Bridgeway Capital Management LLC Has $530,000 Stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Bridgeway Capital Management LLC grew its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 5.0% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 69,072 shares of the company’s stock after buying an additional 3,305 shares during the quarter. Bridgeway Capital Management LLC’s holdings in iTeos Therapeutics were worth $530,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. SG Americas Securities LLC increased its holdings in shares of iTeos Therapeutics by 12.2% during the 4th quarter. SG Americas Securities LLC now owns 13,866 shares of the company’s stock valued at $106,000 after acquiring an additional 1,508 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in iTeos Therapeutics by 16.9% in the 4th quarter. Wells Fargo & Company MN now owns 16,644 shares of the company’s stock worth $128,000 after purchasing an additional 2,402 shares during the last quarter. Virtus ETF Advisers LLC boosted its position in iTeos Therapeutics by 58.2% during the fourth quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company’s stock worth $69,000 after purchasing an additional 3,293 shares during the period. Empowered Funds LLC boosted its position in iTeos Therapeutics by 5.0% during the fourth quarter. Empowered Funds LLC now owns 69,072 shares of the company’s stock worth $530,000 after purchasing an additional 3,305 shares during the period. Finally, Geode Capital Management LLC grew its holdings in iTeos Therapeutics by 0.7% during the fourth quarter. Geode Capital Management LLC now owns 644,901 shares of the company’s stock valued at $4,954,000 after purchasing an additional 4,551 shares during the last quarter. Institutional investors and hedge funds own 97.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Wedbush restated an “outperform” rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a research note on Wednesday, March 5th. JPMorgan Chase & Co. dropped their target price on shares of iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating on the stock in a report on Thursday, March 6th. Wells Fargo & Company cut their target price on shares of iTeos Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a research report on Tuesday, April 29th. Finally, HC Wainwright restated a “buy” rating and set a $46.00 price target on shares of iTeos Therapeutics in a report on Thursday, March 6th.

iTeos Therapeutics Stock Down 0.3%

ITOS opened at $6.68 on Monday. The stock’s 50 day moving average price is $6.55 and its two-hundred day moving average price is $7.44. The firm has a market capitalization of $255.67 million, a P/E ratio of -2.12 and a beta of 1.39. iTeos Therapeutics, Inc. has a 12-month low of $4.80 and a 12-month high of $18.70.

iTeos Therapeutics (NASDAQ:ITOS) last posted its quarterly earnings data on Monday, April 28th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($0.94) by $0.14. As a group, analysts anticipate that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current year.

iTeos Therapeutics Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.